At a glance
ClinicalIndex Comparison RecordN/ACompleted· 167 enrolled
Drug / intervention
AcrySof® IQ PanOptix™ Presbyopia-Correcting IOLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL Model TFNT00
In Brief
A clinical study evaluating AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL for Cataract. Completed, enrolled 167 participants.
Detailed Summary
The purpose of this study is to investigate visual outcomes and assess safety at 12 months (330-420 days) post bilateral implantation of the AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartSep 2015
Primary CompletionNov 2016
Study CompletionJun 2017
TodayJul 2026
First PostedAug 20, 2015
Enrollment StartSep 7, 2015
Primary CompletionNov 30, 2016
Study CompletionJun 26, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.9 years ago
Interventions
AcrySof® IQ PanOptix™ Presbyopia-Correcting IOLdevice
Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient